Musi wa13 Nyamavhuvhu, 2025, Pacific Time, webhusaiti yepamutemo ye2025 World Conference on Lung Cancer (WCLC) yakaburitsa zvidimbu zvetsvagurudzo zvakasarudzwa zvemusangano wegore rino, Pakati pezvinonyanya kukosha pane chidimbu chakagadziridzwa chekuyedzwa kwekutanga kwekiriniki yePhase 1 yeHLX43, Henlius' PD-L1 ADC.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Email：myimmnet@163.com
HLX43 mushonga weADC unodzivirira bundu unoshandiswa pakurwisa PD-L1, une nzira mbiri dzinobatanidza kudzivirira kwekudzivirira muviri uye kukuvadza muviri. Ruzivo rwekutanga rwekiriniki rwakaratidza kuti HLX43 ine mhedzisiro yakanaka yekurwisa bundu uye inogona kushivirira kenza yemapapu isiri diki (NSCLC), kenza yemuromo wechibereko (CC), esophageal squamous cell carcinoma (ESCC), nedzimwe mhando dzebundu dzaisagona kubatwa nePD-1/L1 mAb.
Sekureva kwechinyorwa chakagadziridzwa, HLX43 inoramba ichiratidza kupindura kwakanyanya muvarwere vane bundu rakasimba, kunyanya muvarwere veNSCLC vakamborapwa vasati vawana mushonga wekudzivirira chirwere. HLX43 inoratidza kushanda zvakanaka mumapoka madiki, ine chiyero chekupindura chakakwana (ORR) che47.4% muEGFR wild-type non-squamous NSCLC, uku ichichengetedza kuchengetedzeka kwakanaka. Zvakakosha kuti HLX43 inoratidza kushanda kwakasimba pasinei nekuratidzwa kwePD-L1, zvichiratidza kugona kwayo kurwisa bundu pasina biomarker.
Kushanda Mukurapa Kwekupedzisira kweNSCLC Isingapindi CPI: Kubva Kukadzi 28, 2025, varwere vanosvika 85 vakagamuchira HLX43. MuPhase Ia (kuwedzera kwedosi), varwere 21 vane bundu rakasimba vakanyoreswa, nepo muPhase Ib (kuwedzera kwedosi), varwere 64 veNSCLC vakanyoreswa mumapoka matatu (2, 2.5, uye 3 mg/kg). Zvinonyanya kukosha, 88.2% (75/85) yevarwere vakakundikana kurapwa kwe prerequisited checkpoint inhibitor (CPI).
Kushanda Zvakanaka muNSCLC neMhedzisiro Inoshamisa muMapoka Madiki: Pakati pevarwere veNSCLC 76 (69 vanoongororwa kushanda zvakanaka), ORR yaive 31.9% (22/69), ine chiyero chekudzivirira chirwere (DCR) che87.0% (60/69). Ongororo dzemapoka mashoma dzakaratidza kushanda zvakanaka kweHLX43 mumapoka chaiwo: mapoka e2 mg/kg ne2.5 mg/kg muPhase Ib akawana maORR e38.1% (8/21) uye 33.3% (7/21), zvichiteerana; varwere veNSCLC vasingadyi CPI (n=61) vakaratidza ORR ye32.8% (20/61); varwere veEGFR vasiri squamous NSCLC (n=19) vaive neORR ye47.4% (9/19).
Kuchengetedzwa Kwakanaka, Kushanda Kwakanyanya Nekushaikwa Kwechepfu: MuPhase Ia, chiitiko chimwe chete cheDLT chine chekuita nefibrile neutropenia chakaonekwa muboka re4 mg/kg. Zviitiko zvisina kunaka zvine chekuita nekurapwa (TRAEs) zvakashumwa mu95.2% yevarwere, kunyanya Giredhi 1-2. Giredhi ≥3 TRAEs dzakaitika muvarwere vashanu (23.8%), vese kubva mumapoka e3 ne4 mg/kg, kazhinji nhamba yeneutrophil yakaderera (19%), nhamba yakaderera yemasero machena eropa (19.0%) uye anemia (14.3%). Zviitiko zvisina kunaka zvine chekuita neimmune system (irAEs) zvakashumwa muchidzidzo ichi zvinoratidza kuti HLX43 inokwanisa kukonzera mhedzisiro ye immunotherapy. Zvinoshamisa kuti, varwere vakataura nezve irAEs vakaratidza mwero wepamusoro wemhinduro (ORR).
Inoshanda mune zvakasiyana-siyana zve biomarker: Varwere vePD-L1-positive NSCLC (n=50) vakaratidza ORR ye32.0% (16/50) nepo varwere vePD-L1-negative/vasingazivikanwe (n=19) vakawana ORR ye31.6% (6/19), pasina musiyano wakakosha wakaonekwa.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Email：myimmnet@163.com
Nguva yekutumira: Nyamavhuvhu-15-2025